Background: Liver-related mortality is considered the most common cause of death in HIV/HCV-co infected individuals. Accordingly, treatment of HCV infection in HIV/HCV-co infected individuals is a priority to manage such major health burden. Objectives: To evaluate the safety and efficacy of treatment of chronic HCV by DDAs in HCV-HIV co-infected Egyptian patients. Patients and methods: It is an observational study that included 22 patients; only 18 HCV\HIV co-infected patients completed the study [14 males (77.8 %) and 4 females (22.8 %)]. Their ages ranged from 21 to 46 years with a mean age of 32.89 years. Half of them married and 72% of them working. 61% of them are smokers and IV addicts. Patients were divided into two groups according to HIV PCR. Group I included 12 Patients with HIV PCR > 50 copies/mm and group II that included 6 patients with HIV PCR < 50 copies \mm. Results: The rates of a sustained virologic response (SVR) at post-treatment week 12 (SVR 12) were high [17/18 (94.4%)]. The most common adverse events were fatigue (66.7%), headache (50%) and there was a high safety profile on using direct-acting antivirals (DAAs) and no patient discontinued treatment because of adverse events. No serious adverse events or mortality was reported. In addition, AST & ALT were significantly decreased at end of treatment and 12 weeks after treatment. Otherwise there were no significant changes in both hematological and chemistry labs. Conclusions: Daclatasvir plus sofosbuvir for 12 weeks resulted in a high rate of sustained virologic response in patients co infected with HIV and HCV with high safety profile after treatment completion.
Hegazy, M. E., Fahim, I. B., Sharaf Eldin, M. A., & Gad, S. A. E. (2020). Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients. The Egyptian Journal of Hospital Medicine, 81(4), 1750-1753. doi: 10.21608/ejhm.2020.120005
MLA
Mahmoud Ezat Hegazy; Ihab Barsoum Fahim; Mahmoud Ahmed Sharaf Eldin; Saeed Abd Elbaky Gad. "Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients", The Egyptian Journal of Hospital Medicine, 81, 4, 2020, 1750-1753. doi: 10.21608/ejhm.2020.120005
HARVARD
Hegazy, M. E., Fahim, I. B., Sharaf Eldin, M. A., Gad, S. A. E. (2020). 'Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients', The Egyptian Journal of Hospital Medicine, 81(4), pp. 1750-1753. doi: 10.21608/ejhm.2020.120005
VANCOUVER
Hegazy, M. E., Fahim, I. B., Sharaf Eldin, M. A., Gad, S. A. E. Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients. The Egyptian Journal of Hospital Medicine, 2020; 81(4): 1750-1753. doi: 10.21608/ejhm.2020.120005
)
View on SCiNiTO